Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study.

@article{Douketis2012AccuracyAS,
  title={Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView{\textregistered}) in the diagnosis of deep vein thrombosis: a phase II study.},
  author={James D. Douketis and Jeffrey S. Ginsberg and Susan Haley and Jim A. Julian and Miriam Dwyer and Mark Norman Levine and Paul R. Eisenberg and Richard C. Smart and Wendy W. Tsui and Richard H. R. White and Timothy A. Morris and Scott Kaatz and P C Comp and Mark Andrew Crowther and Clive Kearon and Jeannine Kassis and Shannon M. Bates and Sam Schulman and Louis Desjardins and Raymond Taillefer and Susan M. Begelman and Michael Gerometta},
  journal={Thrombosis research},
  year={2012},
  volume={130 3},
  pages={
          381-9
        }
}
Radiation Dosimetry of the Fibrin-Binding Probe 64Cu-FBP8 and Its Feasibility for PET Imaging of Deep Vein Thrombosis and Pulmonary Embolism in Rats
TLDR
It is shown that 64 Cu-FBP8 PET is a feasible approach to image DVT-PE and that radiogenic adverse health effects should not limit the clinical translation of 64Cu-F BP8.
18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi
TLDR
18F-GP1 binds specifically with high affinity to the GPIIb/IIIa receptor involved in platelet aggregation and is an 18F-labeled small molecule for PET imaging of thrombi.
Evaluation of 111In-labeled EPep and FibPep as tracers for fibrin SPECT imaging.
TLDR
The findings suggest that the FibPep binding fibrin epitope is not fully homologous between humans and rats, and that preclinical rat models of disease should not be employed to gauge the clinical potential of fibPep.
Review Article The role of molecular imaging in diagnosis of deep vein thrombosis
TLDR
Currently available and newly evolving targets and tracers for detection of DVT using molecular imaging methods are discussed.
The role of molecular imaging in diagnosis of deep vein thrombosis.
TLDR
Currently available and newly evolving targets and tracers for detection of DVT using molecular imaging methods are discussed.
State-of-the-Art Imaging for the Evaluation of Pulmonary Embolism
TLDR
The field of pulmonary embolism imaging has demonstrated continuous evolution in both development of novel techniques and improvement in current technologies, resulting in better detection, decreased radiation exposure, and enhanced functional information beyond morphologic characterization of the pulmonary vasculature.
Molecular Imaging of Vascular Thrombosis
TLDR
Recent developments and challenges of molecular imaging of vascular thrombosis involving magnetic resonance imaging, ultrasound and nuclear imaging techniques are reviewed.
Clinical perspectives for the use of total body PET/CT
TLDR
Some situations for whom a TB-PET might help to settle current clinical issues are highlighted to address specific issues encountered in routine clinical practice and thus improve patient care.
Antibody positron emission tomography imaging in anticancer drug development.
TLDR
This approach could potentially increase the power and value of early trials by improving patient selection, optimizing dose and schedule, and rationalizing observed drug responses.
...
...

References

SHOWING 1-10 OF 19 REFERENCES
Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab′ fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial
TLDR
In subjects with acute DVT, 99mTc-DI-80B3 Fab′ was well tolerated with favourable characteristics for the detection of acute venous thrombosis and pharmacokinetics and organ dosimetry were comparable to prior normal volunteer data.
Detection of pulmonary emboli with 99mTc-labeled anti-D-dimer (DI-80B3)Fab' fragments (ThromboView).
TLDR
A new method to diagnose acute pulmonary embolism by single photon emission computerized tomography (SPECT) after administration of (99m)Tc-labeled anti-D-dimer (DI-80B3) monoclonal antibody Fab' fragments demonstrates an acceptable safety profile and avoids exposure to contrast.
Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′
TLDR
99mTc-DI-80B3 Fab’ is well tolerated, is rapidly cleared and exhibits clinically acceptable dosimetry—characteristics well suited to a potential thrombus imaging agent.
Improved imaging of deep venous thrombi during anticoagulation using radiolabelled anti-D-dimer antibodies
TLDR
Clinical results with radiolabelled anti-D-dimer may be more promising than those previously observed with other anti-fibrin antibodies.
Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.
TLDR
Deep-vein thrombosis can be ruled out in a patient who is judged clinically unlikely to have deep-veIn thromBosis and who has a negative D-dimer test, and ultrasound testing can be safely omitted in such patients.
Single photon emission computed tomography of pulmonary emboli and venous thrombi using anti-D-dimer.
TLDR
Infusion of radiolabeled antibody fragments combined with SPECT reliably identified even peripheral thromboemboli of relatively small size, which are difficult to diagnose with currently available imaging techniques, and may enable imaging of PEs, DVTs, or both in the same patient.
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
TLDR
This guideline suggests that clinical assessment of pretest probability of DVT, rather than performing the same tests in all patients, should guide the diagnostic process for a first lower extremity DVT (Grade 2B).
Diagnostic management of clinically suspected acute deep vein thrombosis
TLDR
The elements currently used in making the clinical diagnosis of DVT, including clinical decision rules and D‐dimer testing, different imaging investigations and the appropriate use of these within diagnostic algorithms in patients with clinically suspected DVT are discussed.
...
...